General Information
Version
2.18
Revision date
2025-04-14
Product name
Golimumab Formulation
1.2.1 Relevant identified uses
Pharmaceutical
Emergency telephone
353 214329300, 1-908-423-6000
Icons in SDS
Company Information
company name
MSD
e-mail address of the competent person responsible for the Safety Data Sheet
EHSDATASTEWARD@msd.com
GHS Information
Signal word
Danger
Hazard Codes
Hazard statements (CLP)
H334
Hazard statements
Code
Statements
H334
May cause allergy or asthma symptoms or breathing difficulties if inhaled
Section 2
SECTION 2: Hazards identification
Regulation (EC) No. 1272/2008 Classification of the substance or mixture
Signal word
Danger
Hazard statements
H334 May cause allergy or asthma symptoms or breath- ing difficulties if inhaled.
Response
P304 + P340 IF INHALED: Remove person to fresh air and keep comfortable for breathing. P342 + P311 If experiencing respiratory symptoms: Call a POISON CENTER/ doctor.
Hazardous Ingredients
Golimumab
2.3 Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumula- tive and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.
ECOLOGICAL INFORMATION
The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regu- lation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.
TOXICOLOGICAL INFORMATION
The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.
2.1 Classification of the substance or mixture
Classification (REGULATION (EC) No 1272/2008) Respiratory sensitisation, Category 1 H334: May cause allergy or asthma symptoms or breathing difficulties if inhaled.
